Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages S37-S44

  Parmar, Simrit ^a   de Lima, Marcos ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Indexed keywords

ANTINEOPLASTIC AGENT;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MYELODYSPLASTIC SYNDROME; REVIEW;

ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; TRANSPLANTATION CONDITIONING;

EID: 77953057299     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.018     Document Type: Article

References (66)

1. Nimer, S.D., Myelodysplastic syndromes. Blood 111 (2008), 4841–4851.
2. Deeg, H.J., Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). Hematol Am Soc Hematol Educ Progr, 2005, 167–173.
3. Cutler, C.S., Lee, S.J., Greenberg, P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004), 579–585.
4. Runde, V., de Witte, T., Arnold, R., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21 (1998), 255–261.
5. Greenberg, P., Cox, C., LeBeau, M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997), 2079–2088.
6. Vardiman, J.W., Harris, N.L., Brunning, R.D., The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002), 2292–2302.
7. Malcovati, L., Germing, U., Kuendgen, A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 (2007), 3503–3510.
8. Sierra, J., Perez, W.S., Rozman, C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002), 1997–2004.
9. Alessandrino, E.P., Della Porta, M.G., Bacigalupo, A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112 (2008), 895–902.
10. de Witte, T., Brand, R., van Biezen, A., et al. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br J Haematol, 2009.
11. Oliansky, D.M., Antin, J.H., Bennett, J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 15 (2009), 137–172.
12. Sorror, M.L., Sandmaier, B.M., Storer, B.E., et al. Comorbidity and disease status–based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25 (2007), 4246–4254.
13. Lee, J.H., Lim, S.N., Kim, D.Y., et al. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity. Bone Marrow Transplant, 2009.
14. Sorror, M., Storer, B., Sandmaier, B.M., et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112 (2008), 1992–2001.
15. Pullarkat, V., Blanchard, S., Tegtmeier, B., et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 42 (2008), 799–805.
16. Kontoyiannis, D.P., Chamilos, G., Lewis, R.E., et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110 (2007), 1303–1306.
17. Maradei, S.C., Maiolino, A., de Azevedo, A.M., et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 114 (2009), 1270–1275.
18. de Lima, M., SOS: too many irons in the fire!. Blood 114 (2009), 1137–1138.
19. Nakai, K., Kanda, Y., Fukuhara, S., et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 19 (2005), 396–401.
20. Scott, B.L., Storer, B., Loken, M.R., et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11 (2005), 65–73.
21. Warlick, E.D., Cioc, A., Defor, T., et al. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 15 (2009), 30–38.
22. Castro-Malaspina, H., Jabubowski, A.A., Papadopoulos, E.B., et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell□depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 14 (2008), 458–468.
23. Oran, B., Giralt, S., Saliba, R., et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13 (2007), 454–462.
24. Oosterveld, M., Muus, P., Suciu, S., et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 16 (2002), 1615–1621.
25. Fenaux, P., Mufti, G.J., Hellstrom-Lindberg, E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 (2009), 223–232.
26. Field, T., Perkins, J., Huang, Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 2009.
27. de Padua Silva, L., de Lima, M., Kantarjian, H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43 (2009), 839–843.
28. Jabbour, E., Shan, J., O'Brien, S., et al. Outcome of patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post-decitabine failure. Blood, 2008, 112.
29. Kantarjian, H.M., O'Brien, S., Huang, X., et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher-risk myelodysplastic syndrome: comparison with historical experience. Cancer 109 (2007), 1133–1137.
30. de Lima, M., Giralt, S., Komanduri, K., et al. Maintenance therapy with low-dose azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed or refractory AML or MDS: a dose- and schedule-finding study. Blood, 2008, 112.
31. Jabbour, E., Giralt, S., Kantarjian, H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115 (2009), 1899–1905.
32. de Witte, T., Suciu, S., Verhoef, G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001), 2326–2331.
33. Kroger, N., Brand, R., van Biezen, A., et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 37 (2006), 183–189.
34. de Witte, T., Hermans, J., Vossen, J., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110 (2000), 620–630.
35. Al-Ali, H.K., Brand, R., van Biezen, A., et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia 21 (2007), 1945–1951.
36. Oosterveld, M., Suciu, S., Verhoef, G., et al. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia 17 (2003), 859–868.
37. Deeg, H.J., Storer, B., Slattery, J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002), 1201–1207.
38. Ho, A.Y., Pagliuca, A., Kenyon, M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104 (2004), 1616–1623.
39. Jurado, M., Deeg, H.J., Storer, B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8 (2002), 161–169.
40. Hallemeier, C.L., Girgis, M.D., Blum, W.G., et al. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 12 (2006), 749–757.
41. Nakamura, R., Rodriguez, R., Palmer, J., et al. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant 40 (2007), 843–850.
42. Kroger, N., Bornhauser, M., Ehninger, G., et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82 (2003), 336–342.
43. Laughlin, M.J., Eapen, M., Rubinstein, P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351 (2004), 2265–2275.
44. Ooi, J., Iseki, T., Takahashi, S., et al. Unrelated cord blood transplantation for adult patients with advanced myelodysplastic syndrome. Blood 101 (2003), 4711–4713.
45. Parikh, S.H., Mendizabal, A., Martin, P.L., et al. Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. Biol Blood Marrow Transplant 15 (2009), 948–955.
46. Ooi, J., The efficacy of unrelated cord blood transplantation for adult myelodysplastic syndrome. Leuk Lymphoma 47 (2006), 599–602.
47. Majhail, N.S., Brunstein, C.G., Tomblyn, M., et al. Reduced-intensity allogeneic transplantation in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant 14 (2008), 282–289.
48. Ciurea, S.O., Saliba, R., Rondon, G., et al. Reduced-intensity conditioning using fludarabine, melphalan, and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant, 2009.
49. del Canizo, M.C., Martinez, C., Conde, E., et al. Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation: results from the Spanish registry. Bone Marrow Transplant 32 (2003), 987–992.
50. Couban, S., Simpson, D.R., Barnett, M.J., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100 (2002), 1525–1531.
51. Guardiola, P., Runde, V., Bacigalupo, A., et al. Retrospective comparison of bone marrow and granulocyte colony-stimulating factor–mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLAidentical sibling donors in myelodysplastic syndromes. Blood 99 (2002), 4370–4378.
52. Russell, J.A., Duan, Q., Chaudhry, M.A., et al. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease. Biol Blood Marrow Transplant 14 (2008), 888–895.
53. de Lima, M., Couriel, D., Thall, P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004), 857–864.
54. Scott, B., Deeg, H.J., Storer, B., et al. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. Leuk Lymphoma 45 (2004), 2409–2417.
55. Martino, R., Iacobelli, S., Brand, R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108 (2006), 836–846.
56. Parker, J.E., Shafi, T., Pagliuca, A., et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 119 (2002), 144–154.
57. Scott, B.L., Sandmaier, B.M., Storer, B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006), 128–135.
58. Kojima, R., Kami, M., Kanda, Y., et al. Comparison between reduced-intensity and conventional myeloablative allogeneic stem cell transplantation in patients with hematologic malignancies aged between 50 and 59 years. Bone Marrow Transplant 36 (2005), 667–674.
59. Alatrash, G.A.B., Pelosini, M., Rondon, G., et al. Myeloablative, reduced-toxicity IV busulfan/fludarabine (BuFlu) and allogeneic hematopoietic stem cell transplant (HSCT) for patients in the 6th and 7th decades of life with AML or MDS. Blood, 2008, 112.
60. Schmid, C., Schleuning, M., Hentrich, M., et al. High antileukemic efficacy of an intermediate-intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 41 (2008), 721–727.
61. de Witte, T., Zwaan, F., Hermans, J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74 (1990), 151–155.
62. van Besien, K., Kunavakkam, R., Rondon, G., et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15 (2009), 610–617.
63. Lim, Z.Y., Ho, A.Y., Ingram, W., et al. Outcomes of alemtuzumab-based reduced-intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. Br J Haematol 135 (2006), 201–209.
64. Platzbecker, U., von Bonin, M., Goekkurt, E., et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 15 (2009), 101–108.
65. Small, T.N., Young, J.W., Castro-Malaspina, H., et al. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transplant 13 (2007), 235–244.
66. Chan, G.W., Foss, F.M., Klein, A.K., et al. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Biol Blood Marrow Transplant 9 (2003), 753–759.